BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27839909)

  • 1. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
    Leeman JE; Rimner A; Montecalvo J; Hsu M; Zhang Z; von Reibnitz D; Panchoo K; Yorke E; Adusumilli PS; Travis W; Wu AJ
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):138-145. PubMed ID: 27839909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.
    Gao S; Stein S; Petre EN; Shady W; Durack JC; Ridge C; Adusumilli P; Rekhtman N; Solomon SB; Ziv E
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):253-259. PubMed ID: 28770314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
    Hörner-Rieber J; Bernhardt D; Dern J; König L; Adeberg S; Paul A; Heussel CP; Kappes J; Hoffmann H; Herth FJP; Debus J; Warth A; Rieken S
    Radiother Oncol; 2017 Nov; 125(2):317-324. PubMed ID: 28919006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
    Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
    Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
    Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
    J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence.
    Shintani T; Matsuo Y; Iizuka Y; Mitsuyoshi T; Mizowaki T
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1228-1236. PubMed ID: 29722662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
    Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
    Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.
    Cha MJ; Lee HY; Lee KS; Jeong JY; Han J; Shim YM; Hwang HS
    J Thorac Cardiovasc Surg; 2014 Mar; 147(3):921-928.e2. PubMed ID: 24199757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer.
    Sebastian NT; Merritt RE; Abdel-Rasoul M; Wu T; Bazan JG; Xu-Welliver M; Haglund K; D'Souza D; Kneuertz PJ; Williams TM
    Ann Thorac Surg; 2020 Sep; 110(3):998-1005. PubMed ID: 32353436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Histologic Basis for the Efficacy of SBRT to the lung.
    Woody NM; Stephans KL; Andrews M; Zhuang T; Gopal P; Xia P; Farver CF; Raymond DP; Peacock CD; Cicenia J; Reddy CA; Videtic GM; Abazeed ME
    J Thorac Oncol; 2017 Mar; 12(3):510-519. PubMed ID: 28017592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule.
    Samson P; Rehman S; Juloori A; DeWees T; Roach M; Bradley J; Videtic GMM; Stephans K; Robinson C
    Pract Radiat Oncol; 2018; 8(6):404-413. PubMed ID: 29907514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.